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Context: Small for gestational age (SGA) can be a result of fetal growth restriction, associated with 
perinatal morbidity and mortality. Mechanisms that control prenatal growth are poorly understood.  
Objective: The aim of the present study was to gain more insight into prenatal growth failure and 
determine an effective diagnostic approach in SGA newborns. We hypothesized that one or more 
CNVs and disturbed methylation and sequence variants may be present in genes known to be 
associated with fetal growth.   
Design: A prospective cohort study of subjects with a low birthweight for gestational age. 
Setting: The study was conducted at an academic pediatric research institute. 
Patients: A total of 21 SGA newborns with a mean birthweight below the 1st centile and a control 
cohort of 24 appropriate for gestational age newborns were studied. 
Intervention: Array comparative genomic hybridization, genome-wide methylation studies and 
exome sequencing were performed. 
Main Outcome Measures: The numbers of copy number variations, methylation disturbances and 
sequence variants. 
Results: The genetic analyses demonstrated three CNVs, one systematically disturbed methylation 
pattern and one sequence variant explaining the SGA. Additional methylation disturbances and 
sequence variants were present 20 patients. In 19 patients, multiple abnormalities were found.  
Conclusion: Our results confirm the influence of a large number of mechanisms explaining 
dysregulation of fetal growth. We conclude that copy number variations, methylation disturbances and 
sequence variants all contribute to prenatal growth failure. Such genetic workup can be an effective 




The process of human fetal growth is steered by fetal and maternal genetic factors that affect the 
intrauterine environment to ensure effective nutrient exchange between mother and fetus via the 
placenta. SGA has been defined either as being <10th centile for weight at a given gestational age or as 
having a birth length or weight standard deviation score (SDS) of <-2.0 (<2.3rd centile) (1). SGA can 
be a result of fetal growth restriction (FGR), which is defined as a fetus being unable to reach its 
individual growth potential (2). FGR is associated with significant perinatal morbidity and mortality 
(3) and babies with FGR can be predisposed to metabolic diseases later in life (4).  
 Thirty to fifty percent of the variation in weight at birth can be explained by genetic or 
epigenetic causes (5), which include chromosome imbalances, sequence variants and epigenetic 
disturbances. The London Dysmorphology Database contains over 400 entities associated with 
prenatal growth failure (6). Numerous studies on epigenetic influences, especially DNA methylation 
disturbances, have also been performed (7). Despite this research, mechanisms behind prenatal growth 
failure are only poorly understood, at least in part due to the heterogeneous nature of growth 
disturbances. Consequently, an appropriate diagnostic workup for SGA newborns is not well 
established, and questions remain to what extent which genetic factors contribute, what the optimal 
care pathway is for the child, and how we provide adequate counselling to parents. 
 Aim of the present study is to gain further insight into prenatal growth failure and determine 
whether a combination of genomic analyses is an effective diagnostic approach for SGA newborns. 
We used array comparative genomic hybridization (array-CGH) to detect copy number variations 
(CNVs), genome-wide methylation studies to uncover methylation disturbances, and “whole” exome 
sequencing (WES) to detect sequence variants in a cohort of SGA newborns. We hypothesized that 
CNVs explaining the SGA may be found, disturbed methylation may be present in genes known to be 
aberrantly methylated in low birthweight newborns, and that sequence variants may be present in 






We selected 21 SGA newborns and their parents from the Baby Bio Bank (BBB) and Moore Cohort. 
The BBB contains biological samples and clinical data from 2,515 pregnancies, collected between 
2000 and 2014. The Moore cohort consists of 319 trio samples collected from newborns and their 
parents between 1991 and 1994, including a small FGR cohort. 
 Inclusion criteria for this study included: weight at birth at or below 10thth centile, availability 
of parental samples and absence of major structural malformations, to be in accordance to our study 
aims to study severe IUGR newborns without clues for a specific diagnosis. No pre-eclampsia/HELLP 
syndrome, maternal systemic disease, medication use during pregnancy or maternal smoking was 
present, except one mother (SGA4) who was a moderate smoker during pregnancy and one other 
mother (SGA3) who had pre-existing essential hypertension for which she received treatment. SGA17 
was a pregnancy termination at 22 weeks of gestation (reason unknown to us), and was included 
because of the markedly low weight for gestational age without malformations or other clues for a 
specific diagnosis. 
 A control cohort of appropriate for gestational age (AGA) newborns (n = 24) was selected 
from the Preeclampsia And Non-preeclampsia Database (PANDA) Biobank based on birthweight for 
GA closest to the 50th centile and an equal distribution of GA and mode of delivery in relation to the 
SGA cases. The PANDA Biobank collected placental biopsies, umbilical cord blood samples and 
maternal blood samples of 400 women with either preeclampsia or normotensive pregnancies, between 
2006 and 2010.  
 The SDS of weight at birth were calculated using the 1990 British growth references (8) for 
the British cases and the 1991 reference data for the Dutch controls (9). Descriptive statistics for 
analyzing demographic data was performed in IBM SPSS Statistics, version 22. 
 Ethical approval for all studies was obtained (BBB Research Ethics Committee references: 





We performed literature searches on (1) genes known to be aberrantly methylated in SGA 
(Supplemental Table 1) (2) genes known to be involved in regulation of DNA methylation 
(Supplemental Table 2) and (3) genes in which sequence variants are associated with disorders with 
SGA as part of the phenotype (Supplemental Table 3). These genes will be referred to as ‘targeted 
genes’.  
  
DNA isolation  
DNA was obtained from biopsies from the fetal side of the placenta near the umbilical cord insertion. 
DNA from parental blood samples and the cases were extracted using DNEasy Blood and Tissue Kit 
(Qiagen, CA, USA). DNA from the control samples was biopsied from the maternal site of the 
placenta and extracted according to the Gentra protocol (Qiagen, CA, USA). To minimize the risk of 
maternal blood contamination, placenta biopsies were washed in phosphate-buffered saline and stored 
in RNAlater. To verify whether no maternal DNA contamination has occurred, clustering of male 
samples and female samples was investigated by principal component analysis. 
Array CGH  
The array comparative genomic hybridization (array-CGH) analysis was performed using Agilent 
180K oligo-array (Amadid 023363) (Agilent Technologies, Inc., Palo Alto, CA), with 13kb overall 
median probe spacing and GRCh37/hg19 browser. Standard methods were used for labelling and 
hybridization. Samples were hybridized against a pool of 40 healthy sex-matched human reference 
samples. Data were analyzed with Genomic Workbench 6.5 (Agilent, Santa Clara, CA and Cartagenia 
(BENCHlab CNV v5.0 (r6643)). 
Genome-wide methylation array  
Bisulfite conversion of genomic DNA was performed using EZ DNA Methylation Kit (Zymo 
Research, CA, USA). Converted DNA samples were randomized across one batch and hybridized on 
Infinium Human Methylation 450K BeadChip array (Illumina, Inc., CA, USA), carried out by a 
certified Illumina service provider (ServiceXS, Leiden, the Netherlands). The 450K BeadChip applies 
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both Infinium I and II assays and examines >450.000 CpG sites across the genome. Due to the 
bisulfite conversion, the array recognized methylated and unmethylated loci and expresses the degree 
of methylation in β-values, ranging from 0 (fully unmethylated) to 1 (fully methylated). 
 Quality control of the Illumina 450k assay was performed using MethylAid (10). Raw data 
were provided by ServiceXS and used for statistical analysis. A file containing the β-value 
methylation data including annotation was produced by GenomeStudio. Methylation data from 
GenomeStudio and sample phenotype data were exported to R statistical analysis environment (R 
version 2.15.2) (http://www.r-project.org), where a single sample analysis (11) was performed. This 
allows analysis of genome-wide methylation data in small sample sizes, where each case is 
individually compared to a control cohort. The method combines Illumina Methylation Analyzer 
(IMA) package (version 3.2.1) and Crawford-Howell t-test (11). The IMA package performs a basic 
quality control and pre-processes methylation data. Any CpG sites with missing values and samples 
with  >75% CpG sites having a p-value >0.05, CpG sites where >75% samples have detection p-value 
>1e-5, probes on the X and Y chromosomes and probes containing SNP(s) were removed. The β-values 
were converted to M-values by logit transformation (12). Quantile normalization was used to reduce 
unwanted technical variation across samples. Peak correction (13) was applied to correct differences 
between Infinium I and Infinium II type assays. As all cases and controls were hybridized on the same 
batch, no batch correction was required. Differences between pre-processed M-values of all single 
cases and the controls were determined using Crawford-Howell t-test.  
 Given the large number of significantly differentially methylated probes in our patients 
resulting from the single sample analysis, a script in Python (version 2.7) (https://www.python.org/) 
was used for further filtering of data. Probes with a β value difference of at least 20%, adjusted p-value 
<0.05 and a minimum of three differentially methylated probes within 2000 base pairs, allowing for 
reduction of false positive findings, were selected for hypermethylated and hypomethylated probes, 
respectively. Probes without gene annotation were removed from further analysis. Genes found to be 
hypermethylated and hypomethylated at the same time in the same patient were removed. First, 
genome-wide methylation patterns in SGA newborns were analyzed against previously reported 
literature (Supplemental Table 1). Second, other genes that were differentially methylated in >5 
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patients were selected.  
  In order to investigate the significance of the present methylation findings, we analysed the 
cohort of controls as if they were cases: the results in a single control was analysed against the 
remaining controls, and this was performed for each control. We carried out this analysis for the 
candidate genes as well as for the untargeted genes differentially methylated in >5 controls.   
  For the permutation analysis, the fraction of probes showing significant differential 
methylation (p-values below the threshold of 1.0e-2) were compared between the 50 candidate genes 
and randomly selected 50 genes within the same sample. This random selection was carried out 1000 
times per sample and the mean value was generated for the comparison. The fraction of the probes 
having significant differential methylation is expected to be higher in the 50 candidate genes compared 
to the 50 randomly selected samples. If it is significantly higher, the permutation p-value would be less 
than 0.05, making them more likely candidates.  
 
Exome sequencing  
“Whole” Exome Sequencing (WES) was performed by BGI (Hong Kong). In total 41 samples were 
analyzed using Agilent SureSelect Human All Exon V5 (50M) kit and high throughput sequencing 
technology of Complete Genomics, at 100x coverage. The samples consisted of 10 trios from 
newborns with the lowest birthweights and their parents (SGA1, SGA3, SGA6, SGA15 – SGA21) and 
11 singletons of the remaining newborns. For each sample BGI analyzed and provided reads, results of 
mappings, and basic bioinformatics analysis (including alignment and assessment, SNP and InDel 
calling, basic annotation and statistics, SNP validation). At our institution data were further annotated, 
including pathogenicity prediction data, allowing for subsequent filtering of variants. Variants were 
kept for further examination if mutation types (SO terms) with “high” and “moderate” impact 
(Ensembl Variation - Predicted data, ensemble.org), 1K genome minor allele frequency (MAF) <0.05, 
ExAC allele frequency <0.05, read depth ≥30, quality score ≥30. Variants with known non-pathogenic 
significance and a combined SIFT and PolyPhen prediction of “tolerated” and “benign” were 
discarded. 
 Subsequently, we checked variants in targeted genes known to cause a low birth weight 
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(Supplemental Table 3), and determined the likelihood of pathogenicity. Ethnicity-specific MAF 
were obtained from 1000 Genome, ExAC and GO-ESP databases. Second, potential de novo variants 
were selected and verified in IGV (Integrative Genomics Viewer, Broad Institute) in the 10 patients of 
whom sequencing results from both newborn and parents were available. Lastly, homozygous and 
compound heterozygous mutations were analyzed. All variants in genes discussed in Results and 




All 21 SGA cases (SGA1 – SGA21) had a birth weight (BW) for gestational age (GA) below the 3.4th 
centile, 19 were below the 2.3nd centile and 14 patients below the 1st centile. Table 1 shows other 
demographics of the study group and the control samples. Separate clustering of male cases and 
control samples from female samples was confirmed, indicating that no maternal DNA contamination 
was measured (Supplemental Figure 1).  
Array CGH 
The array-CGH yielded abnormalities in three patients. Patient SGA1 showed a mosaic trisomy of 
chromosome 16 in 70% of the cells (arr[19] 16p13.3q24(64,381-90,163,114)x2~3). Another mosaic 
imbalance, mosaic Turner syndrome, was seen in patient SGA11 (arr Xp22.33q28(61,091-
155,009,479)x1~2). Patient SGA17 had a deletion of 11p13-p14.1 (arr[h19] 11p14.1p13(29,663,942-
33,400,789)x1) causing WAGR syndrome (Wilms tumor, Aniridia, Genital anomalies and mental 
Retardation).  
Genome-wide methylation   
Quality control of the Illumina 450k assay showed no failed samples for bisulphite conversion, 
hybridization and overall methylation threshold. Table 2 shows methylation changes in genes known 
to be aberrantly methylated in low birthweight newborns which we targeted first (see Methods and 
Supplemental Table 1). Differential methylation was seen in 12 patients of which nine had 
differential methylation in more than one gene. As patient SGA3 shows an extensively aberrant 
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methylation profile (Figure 1), the results for this patient are presented separately. Subsequently, all 
genes found in an untargeted study to be differentially methylated in five or more patients, were 
analysed (Supplemental Table 4), showing 28 hypermethylated genes and 6 hypomethylated genes. 
Analysis of our control cohort showed 45 differentially methylated genes present in >5 individuals. 
Out of the 34 genes resulting from the case analysis, in total 12 genes (35%) appeared to be the same 
genes. SGA3 showed differential methylation in 26 targeted genes known to be aberrantly methylated 
in low birthweight newborns (Supplemental Table 5). A possible explanation for this extensively 
disturbed methylation pattern in SGA3 would be an alteration in a gene known to be involved in (the 
regulation of) DNA-methylation (see Methods and Supplemental Table 2). Of these, four were 
hypermethylated and 11 hypomethylated (Supplemental Table 6). Additionally, WES data were 
checked for sequence variants in genes involved in regulating DNA-methylation (Supplemental 
Table 6), showing a heterozygous missense mutation in MPHOSPH8 (p.Asp460Tyr). The same 
variant, with a known minor allele frequency (MAF) of 2-3% (rs75390100), was found in two other 
patients (SGA2 and SGA15). This high MAF excludes this variant to be the sole  (Mendelian) cause of 
the IUGR but we cannot exclude that it contributes to a polygenic or multifactorial origin of the IUGR. 
 Due to an administrative error, three samples (SGA5, SGA9 and SGA12) could not be 
included in the genome-wide methylation analysis.   
  Analysis of the control cohort yielded a total of eight of the targeted genes (CDKN1C, NPR3, 
NR3C1, FOXP1, H19, TBX15, WNT2 and ZIC1) that were differentially methylated. Seven of those 
genes were also found in our case analysis with a comparable number of individuals and methylation 
in the same direction as the cases (or both hypermethylation and hypomethylation). The permutation 
analysis showed the probes within the 50 candidate genes resulting from our study (Table 2 and 
Supplemental Table 5) had consistently higher fraction of probes below the threshold value 
compared to the randomly selected genes, except for four patients (Supplemental Table 7). In 
addition, 7/18 samples had P-values <0.05. 
Exome sequencing 
Exome sequencing without filtering yielded over 70,000 single nucleotide variants and ~5.000 InDel 
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variants in the 21 patients studied. After filtering (see Methods) we first evaluated sequence variants in 
genes that if mutated are known to be associated with disorders in which a low birthweight is part of 
the phenotype (Supplemental Table 3). This targeted analysis yielded potentially pathogenic 
heterozygous variants in 32 genes, one homozygous variant and two compound heterozygous variants 
(Supplemental Table 8). In this targeted gene panel, no de novo variants were identified in newborns 
of whom sequencing data of the parents were available. In patients in which no WES was performed 
in their parents, variants were sequenced by Sanger in parents and showed inheritance of all variants 
from one or both parents.  
 Second, de novo variants in untargeted genes were analyzed in silico (see Methods). Two de 
novo single nucleotide variants were predicted to be potentially pathogenic (Supplemental Table 8). 
Third, we analyzed all WES data for homozygous variants in untargeted genes, and found three 
homozygous missense mutations of potential interest (Supplemental Table 8). Lastly, we evaluated 
data for compound heterozygous mutations in untargeted genes and found one compound 
heterozygous variant (Supplemental Table 8). All variants described have been validated by Sanger 
sequencing. The recommendation of the American College of Medical Genetics and Genomics was 
followed in interpreting variants. 
 
Discussion  
In the present study we investigated 21 SGA newborns using a combination of array-CGH, genome 
wide methylation array and exome sequencing. In four patients (19%), we found a genetic 
abnormality that likely contributes to their low birthweight.  
 Three CNVs (14%) were detected in the present cohort, a relatively higher number compared 
to previous reports in patients with SGA or short stature (14). Mosaic trisomy 16 is known to lead to 
a high risk of prenatal abnormalities (15), frequently including SGA, and can thus be considered a 
valid explanation for SGA in patient SGA1. Patient SGA11 showed mosaicism for monosomy X. 
About 50% of individuals with Turner syndrome have a mosaic karyotype (16), and it typically 
includes a low birth weight. In patient SGA17 an 11p14.1-p13 deletion, as seen in WAGR syndrome, 
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was identified. This syndrome features reduced intrauterine growth as a known phenotype (17).  
  
 As hypothesized in advance, methylation disturbances in several genes known to be aberrantly 
methylated in low birthweight newborns, were found. In general, more hypermethylation than 
hypomethylation was found in the present cohort. A methylation abnormality potentially involved in 
SGA was detected in 13 patients, of which five showed differential methylation in several imprinted 
genes from the 11p15.5 imprinted region associated with fetal growth restriction, including 
CDKN1C, KCNQ1, IGF2AS, INS and IGF2 (18). However, when each control was analyzed versus 
the remaining controls, similar to the case analyses, similar differential methylation of the majority 
of these genes in control individuals were found. This suggests that these findings are not significant 
as a Mendelian cause for the disturbed intrauterine growth. On the other, hand, the control versus 
controls analyses also showed that the differential methylation of KCNQ1, IGF2AS, INS and IGF2 
were solely differently methylated in the case series, which increases the likelihood (but does not 
prove) these contribute to fetal growth restriction. In addition, probes within the candidate genes had 
consistently higher fraction of probes below the threshold value compared to the randomly selected 
genes in the majority of cases, as shown in the permutation analysis. Seven out of 19 samples 
showed a permutation p-value <0.05, when only one would be expected by chance. Therefore, these 
results were consistent with the overall findings of this study: the 50 candidate genes showed 
differences in a small proportion of the patients, some of whom also carried potential genetic 
variants as well. 
 Methylation disturbances in untargeted genes were considered if the disturbance was present 
in at least 5 patients. Such changes were detected in 34 genes, six of these (PIK3R1, DIXDC1, 
ESRRG, TBX15, GGT1 and FGF8) appeared to be of specific interest, in view of their known 
functions. However, given thatanalysis of the control cohort yielded a similar amount of genes 
including overlap in 12 genes between the cases and controls, these results are unlikely to be 
significant, at least when considering them as Mendelian causes for the FGR.  
 Although promoter methylation is generally associated with reduced gene expression and 
methylation of a gene itself typically with increased gene expression (19), DNA methylation differs 
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pre- and postnatally both quantitatively and in terms of CpG versus non-CpG methylation in utero. 
Therefore, hypermethylation does not necessarily lead to decreased transcription and 
hypomethylation to increased transcription Furthermore, the location of the hypermethylated or 
hypomethylated region within the gene can be crucial in relation to the consequences for expression: 
for example, methylation of a promoter can cause a reduced gene expression while methylation of 
exons to increased gene expression. Therefore, understanding the consequences of the direction of 
differential methylation currently remains uncertain. RNA expression studies should provide insight 
in the consequences of the hyper- and hypomethylation detected in the present candidate genes. 
 In contrast to the generally more frequent hypermethylation profile in the present cohort, 
patient SGA3 showed a predominant hypomethylation pattern and an extensively disturbed 
methylation profile. First, an external epigenetic influence, such as tobacco smoke or infectious 
pathogens, could be the cause of this observation (20). The essential hypertension of SGA3’s mother 
may be of importance in this respect. Second, a mutation in genes regulating DNA methylation, such 
as the DNMTs and TETs(21), could theoretically cause widespread DNA methylation disturbances. 
Also maternal mutations in so called ‘maternal-effect genes’ such as NLRP5, NLRP7 I and 
KHDC3L(22) can cause multi-locus imprinting disturbances in their offspring, usually resulting in 
hypomethylation at multiple loci and seen primarily in female offspring (23). We were unable to 
detect any of such mutations in SGA3. Lastly, disturbed methylation of 15 genes known to be 
involved in (regulation of) DNA methylation was present in SGA3. Especially the abnormal 
methylation of DNMT1, DNMT3B, TET1, UHRF1 and ZFP57 may be of interest as abnormal 
methylation of one of these may have had a subsequent extensive effect.  
 The evaluation of exome sequencing, targeted for genes associated with disorders in which a 
low birthweight is part of the phenotype, uncovered 37 sequence variants in 35 genes. In evaluating 
results we took into account the variability of pattern of inheritance of variants in a single gene, and 
the possibility that variants may not act in a Mendelian manner but can also act in a polygenic or 
multifactorial manner. Each reported finding may be involved in fetal growth restriction since if 
mutated, these genes can cause malformation syndromes, skeletal dysplasias and endocrine 
disorders. Our analyses showed several sequence variants that are plausible candidates for causality, 
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while the majority remain of uncertain significance. One strong candidate is the splice acceptor 
variant in SOS1 (c.3347-1G>A). This variant has been described previously in patients with Noonan-
syndrome and IUGR (24). Given the earlier reported patients and the low MAF, this variant deserves 
further investigation to confirm its potential pathogenic nature. When assessing the different 
sequence variants for potential pathogenicity, it is important to stress that in our opinion it is likely 
that in most patients the cause of FGR will not be monogenic but rather polygenic. This implies that 
there will be changes in either one or more gene and/or in the methylation pattern, such that each 
individually will not cause a major health problem (and will be present in controls as well). In this 
multifactorial model, combinations of a series of such changes will lead to disturbed growth. The 
size of the present study is too limited to reveal complex interactions, however, to provide 
comparison to future studies, sequence and differential methylation data is available in the 
Supplemental Tables.  
 We found de novo mutations in two untargeted genes. MTUS1 is a tumor suppressor gene 
controlling cell proliferation, however no function interfering with fetal growth is known so the 
meaning of this variant remains uncertain. The protein encoded by LZTS2 acts as a tumor suppressor 
and is involved in regulating embryonic development by the Wnt signaling pathway. Homozygous 
mutations were found in four genes, all of uncertain significance. One patient was homozygous for 
the p.Val316Ala variant in MTHFD1. MTHFD1 is important for folate metabolism and embryonic 
development and a mutation in this gene has been associated with fetal hypotrophy. Given the 
contradictory classifications by the prediction programs, the significance of this variant is uncertain. 
Compound heterozygous variants of interest were found in two targeted genes and one untargeted 
gene, all likely benign or of uncertain significance.  
 Our results do not indicate the presence of a single, unifying theme explaining the 
dysregulation of fetal growth, and confirm previous findings that growth in utero is influenced by a 
large number of genes. We demonstrate that there is no predominant type of genetic abnormality 
present in SGA newborns: copy number variations, methylation disturbances and sequence variants 
may all contribute in part to the phenotype. In 19 patients, combinations of a CNV, (multiple) 
sequence variants and (multiple) methylation disturbances are present. Each of these will require 
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detailed and sophisticated investigations to better understand their significance. Our results mirror a 
similar study in children with postnatal growth failure (25), using a similar approach in evaluating 
variants in genes known to be associated with short stature as well as studying variants in other, 
untargeted genes (25). The latter authors highlight the multitude of genetic causes for short stature 
and the complexity of interpretation of variants and their pathogenicity, which resembles the 
observations in the present study.  
 We acknowledge limitations of the present study. The size of our cohort is small and the 
power to draw general conclusions is limited. The genetic heterogeneity within the present cohort 
also appears high. We therefore used an individual-based data analysis approach for the methylation 
study to enable suitable data analysis. Using filtering strategies based on population allele 
frequencies as in the present study limits the ability to determine the pathogenicity of WES variants, 
since such data lack individual phenotypic data. Ideally, for future studies our AGA newborns should 
be sequenced to serve as a control population to allow determining pathogenicity of combinations of 
variants detected by exome sequencing. Furthermore, we had no access to clinical follow-up data of 
the presently studied cohort. The large number of variants of uncertain significance inhibits 
investigating each individual variant extensively; ideally, each variant would require a separate, 
detailed study.  
 We conclude that copy number variations, methylation disturbances and sequence variants 
may all contribute in part to prenatal growth failure. This study shows genetic disturbances in SGA 
are complex and likely polygenic. The results of these studies in individual patients may have 
important consequences for patient care and counselling of patients and their families. Further 
research is still required to determine whether such genetic workup can become an effective 
diagnostic approach in SGA newborns. 
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Figure 1. Number of Differentially Methylated Probes per Patient 
 
Legend Figure 1.  
Total number of differentially methylated probes per patient out of 485,577 interrogated probes, after single case analysis and further probe filtering (see 
Methods). An extensively disturbed methylation profile is evident in patient SGA3, and patient SGA15 has an increased number of hypermethylated probes in 
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Legend Figure 1. Total number of differentially methylated probes per patient out of 485,577 interrogated probes, after single case analysis and further probe filtering (see 
Methods). An extensively disturbed methylation profile is evident in patient SGA3, and patient SGA15 has an increased number of hypermethylated probes in comparison to 
the other patients.  
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GA=gestational age; BW=birth weight; SDS=standard deviation score  
Patient ID Gender GA BW (grams) BW (centile) BW (SDS) Ethnicity Mode of delivery 
Cases 
SGA1 Female 33.00 1220 0.41 -2.64 Caucasian Caesarean section 
SGA2 Female 38.00 1980 0.51 -2.57 African Vaginal 
SGA3 Female 33.71 640 4.7E-5 -4.91 South American Caesarean section 
SGA4 Female 39.00 2435 3.36 -1.83 Caribbean Caesarean section 
SGA5 Female 34.00 1350 0.59 -2.52 Asian Caesarean section 
SGA6 Female 39.57 2120 0.22 -2.85 Caucasian Vaginal 
SGA7 Male 38.00 2080 0.69 -2.46 South American Vaginal 
SGA8 Male 38.00 2140 1.04 -2.31 Caucasian Vaginal 
SGA9 Male 34.43 1543 1.04 -2.31 Caucasian Caesarean section 
SGA10 Male 39.57 2320 0.62 -2.50 Caucasian Vaginal 
SGA11 Female 38.57 2180 1.10 -2.29 African Caesarean section 
SGA12 Female 39.00 2385 2.56 -1.95 African Caesarean section 
SGA13 Male 38.57 2280 1.36 -2.21 Asian Caesarean section 
SGA14 Female 37.14 2017 1.83 -2.09 Caribbean Vaginal 
SGA15 Female 31.71 474 3.14E-4 -4.52 Caucasian Caesarean section 
SGA16 Male 39.00 2090 0.24 -2.82 African Caesarean section 
SGA17 Male 22.00 236 0.13 -3.00 Caucasian Termination of 
pregnancy 
SGA18 Male 36.00 1600 0.21 -2.86 Caucasian Caesarean section 
SGA19 Male 37.00 1782 0.26 -2.80 Caucasian Caesarean section 
SGA20 Male 40.00 1874 0.01 -3.69 Caucasian Vaginal 
SGA21 Male 40.00 2220 0.20 -2.88 Caucasian Vaginal 
Mean ± SD - 36.49 ± 4.14 1760 ± 640 0.78 ± 0.88 -2.76 ± 0.77 - - 
Controls 






























Comparison with control cases 


















Imprinted gene in 11p15.5 region, highly expressed in 
placenta. Upregulation associated with IUGR placentas, loss 
of function associated with Beckwith-Wiedemann syndrome, 
gain of function with Silver-Russel syndrome* 
Hypermethylation 1 
SGA4 FGF14 13 (103052362-103052943) 0.16 0.44 3 Hypomethylation associated with SGA or FGR - - 
SGA13 GNAS; 
GNASAS 
20 (57414162-57414539) 0.62 0.83 3 Hypomethylation of GNASAS associated with SGA. 





























Hypermethylation associated with  FGR 
 
Hypermethylation 3 
SGA14 NR3C1 5 (142784522-142785258) 0.22 0.47 3 
 
Differential methylation in  this glucocorticoid receptor in 












































































Decreased methylation associated with SGA or FGR Both 6** 




















IGF2 is imprinted and highly expressed in placenta, 
hypomethylation of H19/IGF2 control region is associated 
with FGR.  INS-IGF2 involved in growth and metabolism. 














Upregulated KCNQ1 and loss of KCNQ1OT1 associated 
with IUGR; genetic variants of KCNQ1 associated with 
Beckwith-Wiedemann syndrome 
- - 
SGA1 TBX15 1 (119526060-119527377) 0.68 0.42 4 Promotor hypomethylation leads to TBX15 decrease in FGR 
placentas 
Both 1** 





For references see Supplemental Table 1; *Clinical diagnosis uncertain due to unavailable detailed phenotyping, ** controls with methylation in same direction as case.  
